Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vyzulta (latanoprostene bunod ophthalmic solution) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• LBN vs. Unoprostone: Latanoprostene bunod (LBN) demonstrated a significant reduction in intraocular pressure (IOP) with a mean difference of -3.45 mmHg (95% CI: -4.77 to -2.12) compared to unoprostone.
• LBN vs. Other Prostaglandin Analogues (PGAs): LBN showed a non-significant reduction in IOP compared to latanoprost (-0.70 mmHg; 95% CI: -1.83 to 0.43), tafluprost (-0.41 mmHg; 95% CI: -1.87 to 1.07), bimatoprost 0.01% (-0.02 mmHg; 95% CI: -1.59 to 1.55), and was slightly less effective than bimatoprost 0.03% (-0.17 mmHg; 95% CI: -1.42 to 1.07).
• LBN vs. Beta-blockers: LBN was significantly more effective in lowering IOP compared to several beta-blockers, including apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, and timolol.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.